Myb-CBP inhibitors (Memorial Sloan-Kettering Cancer Center/Dana-Farber Cancer Institute/Columbia University Medical Center)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameMyb-CBP inhibitors (Memorial Sloan-Kettering Cancer Center/Dana-Farber Cancer Institute/Columbia University Medical Center)
Drug Alias NameMYBMIM
ClassificationSmall molecules > Peptidomimetic
Mechanisms of ActionTranscriptional activator Myb inhibitorscAMP-response element binding protein modulators
TargetscAMP-response element binding proteinTranscriptional activator Myb
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteMemorial Sloan Kettering Cancer CenterColumbia University Medical Center
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A